Toyama Chemical also conducts research in the development of anti-inflammatory agents for diseases such as rheumatoid arthritis (RA) and osteoarthritis. These are more than 0.7 million patients with RA in Japan, and 6.5 million overseas. Recently, several new drugs show the strong efficacy in RA patients, but they have some important problems like serious adverse effects, and so on. Toyama Chemical collaborates with organizations in Japan and overseas for efficiency in development of new drugs.
Subjects of research
Through the latest findings of iguratimod's mode of action, Toyama Chemical is investigating its further potential of new applications in the inflammatory field.